VIVUS, Inc. (VVUS) Announces Acceptance of Avanafil Application in Europe
3/26/2012 10:23:49 AM
MOUNTAIN VIEW, Calif., March 26, 2012 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS) today announced that a Marketing Authorization Application (MAA) has been accepted by the European Medicines Agency (EMA) for the review of avanafil, its investigational drug for the treatment of erectile dysfunction (ED). The EMA submission follows the successful completion of an extensive phase 3 program for avanafil, which included over 1,350 patients.